Lusutrombopag
Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta. It was approved by the FDA in July 2018 and NICE in January 2020.
It was approved for medical use in the European Union in February 2019.
